The lncRNA VELUCT strongly regulates viability of lung cancer cells despite its extremely low abundance.
Little is known about the function of most non-coding RNAs (ncRNAs). The majority of long ncRNAs (lncRNAs) is expressed at very low levels and it is a matter of intense debate whether these can be of functional relevance. Here, we identified lncRNAs regulating the viability of lung cancer cells in a high-throughput RNA interference screen. Based on our previous expression profiling, we designed an siRNA library targeting 638 lncRNAs upregulated in human cancer. In a functional siRNA screen analyzing the viability of lung cancer cells, the most prominent hit was a novel lncRNA which we called Viability Enhancing LUng Cancer Transcript (VELUCT). In silico analyses confirmed the non-coding properties of the transcript. Surprisingly, VELUCT was below the detection limit in total RNA from NCI-H460 cells by RT-qPCR as well as RNA-Seq, but was robustly detected in the chromatin-associated RNA fraction. It is an extremely low abundant lncRNA with an RNA copy number of less than one copy per cell. Blocking transcription with actinomycin D revealed that VELUCT RNA was highly unstable which may partially explain its low steady-state concentration. Despite its extremely low abundance, loss-of-function of VELUCT with three independent experimental approaches in three different lung cancer cell lines led to a significant reduction of cell viability: Next to four individual siRNAs, also two complex siPOOLs as well as two antisense oligonucleotides confirmed the strong and specific phenotype. In summary, the extremely low abundant lncRNA VELUCT is essential for regulation of cell viability in several lung cancer cell lines. Hence, VELUCT is the first example for a lncRNA that is expressed at a very low level, but has a strong loss-of-function phenotype. Thus, our study proves that at least individual low-abundant lncRNAs can play an important functional role.
Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jana
J
Seiler
Division of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marco
M
Breinig
Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maïwen
M
Caudron-Herger
Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maria
M
Polycarpou-Schwarz
Division of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael
M
Boutros
Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.|Division of Cancer Research, Dept. of Thoracic Surgery, Medical Center - University of Freiburg, Freiburg, Germany.|Faculty of Medicine, University of Freiburg, Freiburg, Germany.|German Cancer Consortium (DKTK), Freiburg, Germany.
Sven
S
Diederichs
D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival / Q000235:genetics; D002843:Chromatin / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology*; D020871:RNA Stability / Q000235:genetics; D062085:RNA, Long Noncoding / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism
D002843:Chromatin; D062085:RNA, Long Noncoding; D012333:RNA, Messenger; D034741:RNA, Small Interfering